Lucid Capital Markets Rates Microbot Medical Stock as Buy with $4 Target
Lucid Capital Markets initiates Microbot Medical stock with buy rating
Image: Investing Australia
Lucid Capital Markets has initiated coverage on Microbot Medical (NASDAQ:MBOT) with a buy rating and a price target of $4.00, indicating a potential upside of nearly 100% from its current price of $2.01. The company is expanding its market presence with recent product approvals and customer acquisitions.
- 01Lucid Capital Markets set a price target of $4.00 for Microbot Medical, suggesting nearly 100% upside from its current trading price.
- 02The U.S. endovascular intervention market comprises 5 to 6 million procedures annually, with less than 1% currently performed robotically.
- 03Microbot Medical's LIBERTY Endovascular Robotic System has received marketing clearance from Israel’s Ministry of Health, enabling its commercialization in Israel.
- 04The company reported a 17.5% return on its stock over the past week and has a strong current ratio of 22.59, indicating solid liquidity.
- 05Despite skepticism from White Diamond Research, Microbot Medical continues to expand its market presence, having secured its first customer in North Carolina.
Advertisement
In-Article Ad
Lucid Capital Markets has initiated coverage of Microbot Medical (NASDAQ:MBOT) with a buy rating and a price target of $4.00, indicating a potential upside of nearly 100% from its current price of $2.01. The company has demonstrated strong liquidity with more cash than debt and a current ratio of 22.59. The U.S. endovascular intervention market, valued at over $40 billion, sees limited robotic adoption, with less than 1% of procedures currently performed using robotic systems. Microbot's LIBERTY Endovascular Robotic System has recently received marketing clearance in Israel, marking a significant milestone for the company. Additionally, Microbot Medical has reported a 17.5% stock return over the past week and has secured its first customer in North Carolina, expanding its reach in the Southeast and Mid-Atlantic regions. However, skepticism remains regarding the commercial viability of its products, as noted by White Diamond Research, which has set a $1 price target on the stock. Despite this, the company is focused on enhancing its market position and operational capabilities.
Advertisement
In-Article Ad
Microbot Medical's expansion into new markets and product availability could enhance local healthcare options and economic activity in the regions it serves.
Advertisement
In-Article Ad
Reader Poll
What do you think about the investment potential of Microbot Medical?
Connecting to poll...
More about Lucid Capital Markets
Read the original article
Visit the source for the complete story.